We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Advanced Melanoma

Journal Scan / Research · November 05, 2021

Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma

Molecular Cancer Therapeutics

 

Additional Info

Molecular Cancer Therapeutics
Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma
Mol Cancer Ther 2021 Oct 01;20(10)2049-2060, KW Nassar, JD Hintzsche, SM Bagby, V Espinoza, C Langouët-Astrié, CM Amato, TS Chimed, M Fujita, W Robinson, AC Tan, RE Schweppe

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading